Evidence map›Paper›PMID 36557315›Full record

ArticleMetabolites2022

Quantitative Serum NMR Spectroscopy Stratifies COVID-19 Patients and Sheds Light on Interfaces of Host Metabolism and the Immune Response with Cytokines and Clinical Parameters.

Titus Rössler, Georgy Berezhnoy, Yogesh Singh, Claire Cannet, Tony Reinsperger, Hartmut Schäfer, Manfred Spraul, Manfred Kneilling, Uta Merle, Christoph Trautwein

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Titus RösslerWerner Siemens Imaging Center, Department for Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.
Georgy BerezhnoyWerner Siemens Imaging Center, Department for Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.ORCID 0000-0003-0260-3203
Yogesh SinghInstitute of Medical Genetics & Applied Genomics, University Hospital Tübingen, 72076 Tübingen, Germany.ORCID 0000-0001-6919-6273
Claire CannetBruker BioSpin GmbH, Applied Industrial and Clinical Division, 76275 Ettlingen, Germany.
Tony ReinspergerBruker BioSpin GmbH, Applied Industrial and Clinical Division, 76275 Ettlingen, Germany.
Hartmut SchäferBruker BioSpin GmbH, Applied Industrial and Clinical Division, 76275 Ettlingen, Germany.
Manfred SpraulBruker BioSpin GmbH, Applied Industrial and Clinical Division, 76275 Ettlingen, Germany.
Manfred KneillingWerner Siemens Imaging Center, Department for Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.
Uta MerleDepartment of Internal Medicine IV, University Hospital Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0003-1386-3350
Christoph TrautweinWerner Siemens Imaging Center, Department for Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.ORCID 0000-0003-4672-6395
Bruker (Germany) · DESiemens (Germany) · DEHeidelberg University · DEUniversity of Tübingen · DE

Funding

Bruker BioSpin GmbH n.a.
6 · The paper itself

Abstract

The complex manifestations of COVID-19 are still not fully decoded on the molecular level. We combined quantitative the nuclear magnetic resonance (NMR) spectroscopy serum analysis of metabolites, lipoproteins and inflammation markers with clinical parameters and a targeted cytokine panel to characterize COVID-19 in a large (534 patient samples, 305 controls) outpatient cohort of recently tested PCR-positive patients. The COVID-19 cohort consisted of patients who were predominantly in the initial phase of the disease and mostly exhibited a milder disease course. Concerning the metabolic profiles of SARS-CoV-2-infected patients, we identified markers of oxidative stress and a severe dysregulation of energy metabolism. NMR markers, such as phenylalanine, inflammatory glycoproteins (Glyc) and their ratio with the previously reported supramolecular phospholipid composite (Glyc/SPC), showed a predictive power comparable to laboratory parameters such as C-reactive protein (CRP) or ferritin. We demonstrated interfaces between the metabolism and the immune system, e.g., we could trace an interleukin (IL-6)-induced transformation of a high-density lipoprotein (HDL) to a pro-inflammatory actor. Finally, we showed that metadata such as age, sex and constitution (e.g., body mass index, BMI) need to be considered when exploring new biomarkers and that adding NMR parameters to existing diagnoses expands the diagnostic toolbox for patient stratification and personalized medicine.

Indexed as

biomarkerglycoproteininflammationlipoproteinsmetabolomicsSARS-CoV-2

Identifiers

PMID36557315
PMCPMC9781847
OpenAlexW4312196152

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.